Cargando…

Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor

SIMPLE SUMMARY: Strategies to enhance the preferential accumulation and activation of Natural Killer (NK) cells in the tumor microenvironment can be expected to increase the efficacy of NK cell-based cancer immunotherapy. In this study, we report that a bispecific single domain antibody (VHH) that t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toffoli, Elisa C., Sheikhi, Abdolkarim, Lameris, Roeland, King, Lisa A., van Vliet, Amanda, Walcheck, Bruce, Verheul, Henk M. W., Spanholtz, Jan, Tuynman, Jurriaan, de Gruijl, Tanja D., van der Vliet, Hans J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582566/ https://www.ncbi.nlm.nih.gov/pubmed/34771609 http://dx.doi.org/10.3390/cancers13215446

Ejemplares similares

Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Adoptive NK Cell Therapy: A Promising Treatment Prospect for Metastatic Melanoma
por: van Vliet, Amanda A., et al.
Publicado: (2021)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
por: Veluchamy, John P., et al.
Publicado: (2017)

In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer
por: Veluchamy, John P., et al.
Publicado: (2017)

High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status
por: Veluchamy, John P., et al.
Publicado: (2016)

Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34(+) progenitor cell-derived NK cells
por: van Vliet, Amanda A., et al.
Publicado: (2023)

Standardized and flexible eight colour flow cytometry panels harmonized between different laboratories to study human NK cell phenotype and function
por: Veluchamy, John P., et al.
Publicado: (2017)

Positive & Negative Roles of Innate Effector Cells in Controlling Cancer Progression
por: Stolk, Dorian, et al.
Publicado: (2018)

Effects of physical exercise on natural killer cell activity during (neo)adjuvant chemotherapy: A randomized pilot study
por: Toffoli, Elisa C., et al.
Publicado: (2021)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions
por: Lameris, Roeland, et al.
Publicado: (2023)

Specific tumor targeting and activation of Vγ9Vδ2 T cells by bi-specific nanobodies
por: Stam, Anita, et al.
Publicado: (2014)

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies
por: Lameris, Roeland, et al.
Publicado: (2023)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies
por: Goedegebuure, Ruben S.A., et al.
Publicado: (2020)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
por: Floerchinger, Alessia, et al.
Publicado: (2023)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

The effect of everolimus and low-dose cyclophosphamide on immune cell subsets in patients with metastatic renal cell carcinoma: results from a phase I clinical trial
por: Huijts, Charlotte M., et al.
Publicado: (2019)

Redox-dependent regulation of epidermal growth factor receptor signaling
por: Heppner, David E., et al.
Publicado: (2015)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
por: Huijts, Charlotte M., et al.
Publicado: (2018)

Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager
por: Xiao, Xinghui, et al.
Publicado: (2023)

NK cells from malignant pleural effusions are potent antitumor effectors: A clue for adoptive immunotherapy?
por: Vacca, Paola, et al.
Publicado: (2013)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

Self-monitoring of Physical Activity After Hospital Discharge in Patients Who Have Undergone Gastrointestinal or Lung Cancer Surgery: Mixed Methods Feasibility Study
por: de Leeuwerk, Marijke Elizabeth, et al.
Publicado: (2022)

Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Engineering Anti-Tumor Monoclonal Antibodies and Fc Receptors to Enhance ADCC by Human NK Cells
por: Dixon, Kate J., et al.
Publicado: (2021)

Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function
por: Mantesso, Simone, et al.
Publicado: (2020)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients
por: Reiners, Katrin S., et al.
Publicado: (2013)

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

ATP-Mediated Transactivation of the Epidermal Growth Factor Receptor in Airway Epithelial Cells Involves DUOX1-Dependent Oxidation of Src and ADAM17
por: Sham, Derek, et al.
Publicado: (2013)

A Bispecific Antibody to Link a TRAIL-Based Antitumor Approach to Immunotherapy
por: Satta, Alessandro, et al.
Publicado: (2019)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity
por: Kamakura, Daisuke, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_40peip76vnh9jikfdeslsi94gk